GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Tenet Healthcare Corp (NYSE:THC) » Definitions » ROE %

Tenet Healthcare (Tenet Healthcare) ROE % : 63.54% (As of Dec. 2023)


View and export this data going back to 1976. Start your Free Trial

What is Tenet Healthcare ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Tenet Healthcare's annualized net income for the quarter that ended in Dec. 2023 was $976 Mil. Tenet Healthcare's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1,536 Mil. Therefore, Tenet Healthcare's annualized ROE % for the quarter that ended in Dec. 2023 was 63.54%.

The historical rank and industry rank for Tenet Healthcare's ROE % or its related term are showing as below:

THC' s ROE % Range Over the Past 10 Years
Min: -521.48   Med: 37.88   Max: Negative Equity
Current: 44.99

During the past 13 years, Tenet Healthcare's highest ROE % was Negative Equity%. The lowest was -521.48%. And the median was 37.88%.

THC's ROE % is ranked better than
96.39% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.09 vs THC: 44.99

Tenet Healthcare ROE % Historical Data

The historical data trend for Tenet Healthcare's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenet Healthcare ROE % Chart

Tenet Healthcare Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - Negative Equity 173.11 37.88 44.44

Tenet Healthcare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.33 48.17 38.20 28.79 63.54

Competitive Comparison of Tenet Healthcare's ROE %

For the Medical Care Facilities subindustry, Tenet Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenet Healthcare's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Tenet Healthcare's ROE % distribution charts can be found below:

* The bar in red indicates where Tenet Healthcare's ROE % falls into.



Tenet Healthcare ROE % Calculation

Tenet Healthcare's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=611/( (1142+1608)/ 2 )
=611/1375
=44.44 %

Tenet Healthcare's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=976/( (1464+1608)/ 2 )
=976/1536
=63.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Tenet Healthcare  (NYSE:THC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=976/1536
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(976 / 21516)*(21516 / 27951)*(27951 / 1536)
=Net Margin %*Asset Turnover*Equity Multiplier
=4.54 %*0.7698*18.1973
=ROA %*Equity Multiplier
=3.49 %*18.1973
=63.54 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=976/1536
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (976 / 2076) * (2076 / 2892) * (2892 / 21516) * (21516 / 27951) * (27951 / 1536)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.4701 * 0.7178 * 13.44 % * 0.7698 * 18.1973
=63.54 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Tenet Healthcare ROE % Related Terms

Thank you for viewing the detailed overview of Tenet Healthcare's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenet Healthcare (Tenet Healthcare) Business Description

Traded in Other Exchanges
Address
14201 Dallas Parkway, Dallas, TX, USA, 75254
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of June 2023) and over 550 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
Executives
Richard W Fisher director
Roy Blunt director 2702 LOVE FIELD DRIVE, HDQ 4GC, DALLAS TX 75235
Paola M Arbour officer: EVP, Chief Information Officer 14201 DALLAS PARKWAY, DALLAS TX 75254
Stephen H Rusckowski director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Thomas W Arnst officer: EVP, Chief Admin. Officer & GC 14201 DALLAS PARKWAY, DALLAS TX 75254
Tammy Romo director C/O SOUTHWEST AIRINES CO., 2702 LOVE FIELD DR., DALLAS TX 75235
Daniel J Cancelmi officer: Principal Accounting Officer 13737 NOEL ROAD, SUITE 100, DALLAS TX 75240
J Robert Kerrey director NEW SCHOOL UNIVERSITY, 66 W. 12TH STREET, NEW YORK NY 10036
Richard J Mark director 1901 CHOUTEAU AVENUE MC-1310, ST. LOUIS MO 63103
Ronald A Rittenmeyer director 5400 LEGACY DRIVE, PLANO TX 75024
Lisa Y Foo officer: EVP, Commercial Ops 14201 DALLAS PARKWAY, DALLAS TX 75254
Audrey T. Andrews officer: SVP and General Counsel 1445 ROSS AVENUE, SUITE 1400, DALLAS TX 75202
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Howard Hacker officer: EVP, Chief Compliance Officer 14201 DALLAS PARKWAY, DALLAS TX 75254
Marie Quintana officer: EVP, Marketing/Communications 14201 DALLAS PARKWAY, DALLAS TX 75254